| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2006-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2009-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2009522316-A |
| titleOfInvention |
Combination therapy using anti-EGFR antibody and anti-HER2 antibody |
| abstract |
The present invention relates to the combined use of anti-EGFR antibody and anti-Her2 antibody for cancer treatment, particularly suitable for cancers that express high levels of EGFR type and low levels of HER2. In particular, the present invention relates to a monoclonal antibody “Trastuzumab” that opposes the HER2 receptor whose efficacy can be significantly increased in vivo when used in combination with the monoclonal antibody “Matsuzumab” (hmAB 425, EMD 72000) that opposes the EGF receptor. (HERCEPTIN (registered trademark)). Combination therapy is suitable for patients suffering from a cancer having the receptor profile, preferably pancreatic cancer. |
| priorityDate |
2006-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |